Trials / Unknown
UnknownNCT04868253
Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Rose Research Center, LLC · Industry
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This open-label study will evaluate EMB-001, comprised of metyrapone, a cortisol synthesis inhibitor marketed as a diagnostic drug for testing hypothalamic-pituitary-adrenal (HPA) axis function, combined with oxazepam, an anxiolytic and sedative/hypnotic benzodiazepine, to help smokers abstain from smoking during a 12-week trial period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EMB-01 | EMB-001 is a proprietary combination of metyrapone (a cortisol synthesis inhibitor) and oxazepam (a short to medium acting benzodiazepine). |
Timeline
- Start date
- 2021-05-19
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2021-04-30
- Last updated
- 2021-05-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04868253. Inclusion in this directory is not an endorsement.